Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eurotium amstelodami
- Development stage
- Preclinical
- Lead developer
- Stallergenes Greer
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intradermal, Percutaneous, Subcutaneous
01
Overview
*Eurotium amstelodami* is a xerophilic fungus traditionally recognized as a common spoilage organism in low-moisture foods and animal feeds. In a biomedical context, it is identified as one of the primary etiological agents of Farmer's Lung Disease (FLD), a form of hypersensitivity pneumonitis; consequently, its purified and recombinant antigens are utilized in standardized serological diagnostic ELISA tests. Recent preclinical research has explored its potential as a probiotic fungus, demonstrating protective effects against dextran sulfate sodium (DSS)-induced ulcerative colitis and gut-derived liver injury in murine models. The proposed mechanism involves the modulation of gut microbial community structure, restoration of bile acid metabolism via the farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5), and the suppression of inflammatory pathways including TLR4/NF-kB and the NLRP3 inflammasome. Additionally, *E. amstelodami* is utilized in the fermentation of specialty teas (such as Fuzhuan brick tea) and high-temperature Daqu, where it facilitates the bioconversion of flavonoid glycosides into bioactive aglycones and produces secondary metabolites like asperflavin with anti-inflammatory properties.
- Other names
- Aspergillus amstelodami
02
Targets
IgE (Immunoglobulin E)FXR (Farnesoid x-activated receptor)GPBAR1NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)NF-κBTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Eurotium amstelodami.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eurotium amstelodami.